InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | 2026-04-16 | AULT MILTON C III | Director | Purchase | 108.4K | $1.00 | $109K | 116.6K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $1.4M-78.1% | $6.5M-13.3% | $7.4M+43.2% | $5.2M |
| General and administrative | $3.1M-11.5% | $3.5M-53.1% | $7.4M+4.3% | $7.1M |
| Total operating expenses | $4.5M-54.7% | $9.9M-33.2% | $14.9M+20.7% | $12.3M |
| Loss from operations | -$4.5M+54.7% | -$9.9M+33.2% | -$14.9M-20.7% | -$12.3M |
| Interest expense | -$18K-78.5% | -$10K-31.2% | -$8K+83.4% | -$47K |
| Total other expense, net | -$18K-78.5% | -$10K | — | — |
| NET LOSS | -$4.5M+54.6% | -$9.9M+33.1% | -$14.9M-20.4% | -$12.4M |
| Dividend on preferred shares | -$117K | — | — | — |
| Deemed dividend on warrant modification issued with preferred | -$473K | — | — | — |
| NET LOSS ATTRIBUTED TO COMMON SHARES | -$5.1M+48.7% | -$9.9M | — | — |
| Basic net loss per common share | -$11.32+91.4% | -$132.33-478.1% | -$22.89-16250.0% | -$0.14 |
| Diluted net loss per common share | -$11.32+91.4% | -$132.33-478.1% | -$22.89-16250.0% | -$0.14 |
| Basic weighted average common shares outstanding | $451K+507.8% | $74K-88.6% | $650K-99.3% | $89.1M |
| Diluted weighted average common shares outstanding | $451K+507.8% | $74K-99.9% | $97.5M+9.5% | $89.1M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?